The state of California currently has 940 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Kaiser Permanente-Anaheim, Anaheim, California +62 locations
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT04552509
Recruiting
The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time. Radiosurgery is a non-invasive treatme... Read More
Gender:
Male
Ages:
All
Trial Updated:
11/03/2022
Locations: MemorialCare Saddleback Medical Center, Laguna Hills, California
Conditions: Prostate Cancer
Register for Updates
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California +1 locations
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Register for Updates
Establish ProLung Test Measurement Collection Protocol for Future Studies.
NCT04134520
Recruiting
The purpose of this Study is to identify and test different data collection methods to determine which approaches improve the ProLung Testing procedure. Once this Study is complete, the Sponsor plans to evaluate these improvements in future follow up Validation studies that will assess device accuracy using the new measurement collection methods.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2022
Locations: Coastal Pulmonary Associates, Encinitas, California
Conditions: Cancer , Healthy
Register for Updates
Phase I Human Analytics (HALO) Study
NCT05423860
Recruiting
Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders. Additionally, the stud... Read More
Gender:
Male
Ages:
Between 45 years and 90 years
Trial Updated:
10/12/2022
Locations: Desert Medical Imaging, Indian Wells, California
Conditions: Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain Injury
Register for Updates
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT05479578
Recruiting
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving low doses of cyclophosphamide daily may reduce side effects. Dex... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/08/2022
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Register for Updates
Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
NCT03716531
Recruiting
This research study is studying an intervention as a possible treatment for pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: University of California, Irvine, Irvine, California
Conditions: Pancreas Cancer
Register for Updates
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Recruiting
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Redwood City, Redwood City, California
Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma
Register for Updates
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
NCT04725994
Recruiting
This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2022
Locations: USC Norris Comp. Cancer Ctr Hospital, Los Angeles, California
Conditions: Gastric Cancer
Register for Updates
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
NCT05406167
Recruiting
The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), in standard of care (SOC) use in the treatment of local,loco-regionally advanced, and oligometastatic malignancies. In addition, patient costs and charges will be analyzed to quantify the health economic impact of this modal... Read More
Gender:
All
Ages:
All
Trial Updated:
08/05/2022
Locations: City Of Hope, Duarte, California
Conditions: Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal, Cancer Gynecologic, Cancer, Genito-Urinary, Cancers Lymphatic, Cancer Head and Neck
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Providence Medical Foundation - Providence St. Joseph, Fullerton, California +8 locations
Conditions: Breast Cancer
Register for Updates
PET MRI as a Staging Tool for Head and Neck Cancer
NCT04750434
Recruiting
To explore the use of PET/MRI in the staging and pretreatment evaluation of patients with head and neck cancer and to compare this modality to standard PET/CT imaging.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2022
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Head Cancer, Neck Cancer
Register for Updates